Ticker
ADILW

Price
0.04
Stock movement up
+- (%)
Company name
Adial Pharmaceuticals Inc. WT EXP 073123
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Other >
Other
Market cap
-
Ent value
-3.42M
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-94.67%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

ADILW does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count-
EPS (TTM)-0.61
FCF per share (TTM)-0.56

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-16.06M
Net income (TTM)-15.70M
EPS (TTM)-0.61
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash5.75M
Net receivables0.00
Total current assets6.77M
Goodwill248.97K
Intangible assets459.62K
Property, plant and equipment0.00
Total assets7.74M
Accounts payable278.20K
Short/Current long term debt220.25K
Total current liabilities1.33M
Total liabilities2.33M
Shareholder's equity5.41M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-14.30M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-14.30M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-290.17%
Return on Assets-202.74%
Return on Invested Capital-287.25%
Cash Return on Invested Capital-261.80%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.04
Daily high0.04
Daily low0.04
Daily Volume0K
All-time high2.23
1y analyst estimate-
Beta-
EPS (TTM)-0.61
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADILWS&P500
Current price drop from All-time high-98.21%-13.68%
Highest price drop-99.52%-56.47%
Date of highest drop3 Jan 20239 Mar 2009
Avg drop from high-73.50%-11.49%
Avg time to new high91 days13 days
Max time to new high356 days1805 days
COMPANY DETAILS
ADILW (Adial Pharmaceuticals Inc. WT EXP 073123) company logo
Marketcap
-
Marketcap category
Small-cap
Description
Employees
Website
Investor relations
-
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Po...
February 1, 2023
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President...
November 14, 2022
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va...
September 26, 2022
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod...
September 6, 2022
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va.,...
August 22, 2022
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Act...
August 16, 2022
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinki...
July 20, 2022
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ETCHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Compan...
July 18, 2022
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Com...
June 28, 2022
Expects Release of Top-Line Data in JulyCHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharma...
June 27, 2022
Next page